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There is a growing appreciation that cellular metabolism is important in determining the 
course of lymphocyte responses. Additionally, changes in metabolic processes have 
been linked to dysfunctional lymphocyte functions in a number of different diseases. 
While most early studies of metabolic regulation of lymphocyte function focused on 
T lymphocytes, an understanding of how metabolic pathways impact upon natural killer 
(NK) cell responses is now starting to emerge. In this review article, we will discuss how 
cellular metabolism influences lymphocyte function with a particular focus upon NK cells.
Keywords: natural killer cells, metabolism, mTORC1 signalling, glycolysis and oxidative phosphorylation, innate 
immune response, adaptive immune response, glucose, viral infection, tumor immunotherapy
inTRODUCTiOn
Natural killer (NK) cells are important effector lymphocytes that are best characterized for their 
antiviral and anticancer activities (1, 2). They carry out direct cytotoxicity of target cells and are 
potent producers of IFNγ cytokine. In addition to their effector functions, NK cells can also regulate 
development of the adaptive immune response in a variety of ways including production of immune 
modulating cytokines and regulating DC maturation (3). As NK cell responses can be detected very 
rapidly after infection (within hours), they have historically been classified as cells of the innate 
immune system. However, this textbook viewpoint has changed with the discovery of long-lived and 
sustained functional NK cells, and the demonstration of intrinsic innate immune memory (4–6).
Natural killer cells are also clinically important and represent a good target for anticancer immune 
therapy in which the host immune system is harnessed for anticancer activities. Currently, NK cells 
are being investigated in clinical trials using a range of different approaches. These include direct 
activation in vivo by blocking various inhibitory NK cell receptors using antibodies against KIR and 
NKG2A (see www.innate-pharma.com). Recently, one such trial investigating an anti-KIR antibody 
as a single agent for the treatment of acute myelogenous leukemia (AML) did not reach its primary 
efficacy endpoint and was halted. However, given the promising results in preclinical studies (7), it 
will be interesting to see the results of several other trials still on-going that use these antibodies in 
combination with other agents for a range of cancer types.
Natural killer cells (allogeneic, haploidentical) are also successfully being used for adoptive 
transfer treatment of AML (8–10). Adoptive transfer therapy allows the potential to genetically 
manipulate NK cells prior to infusion. This concept is being explored in a number of clinical trials 
(NCT01974479 and NCT00995137) that have generated chimeric antigen receptor (CAR) NK cells, 
designed to recognize and treat B cell acute lymphoblastic leukemic. While these trials are using 
primary NK cells, there is also some evidence that CAR-modified NK cell lines (NK-92) can provide 
benefit in different preclinical models (11, 12). Finally, NK cells are important in particular antibody-
mediated immunotherapy settings, for instance for the treatment of neuroblastoma or lymphoma 
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where they mediate antibody-dependent cellular cytotoxicity 
(ADCC) against tumor cells (13). Understanding the relevance 
of metabolism to NK  cell effector functions will provide new 
mechanisms to enhance these therapeutic approaches but also 
opens up the potential for new avenues of NK cell-based therapies 
as discussed below.
MeTABOLiSM AnD LYMPHOCYTe 
ReSPOnSeS
It is becoming clear that metabolism is profoundly important for 
immune function, to the extent that manipulation of metabolism 
can alter immune cell fate and function. Immune responses involve 
highly dynamic changes in immune cell function, which often 
encompass robust cellular growth and proliferation. Therefore, it 
is not surprising that there are corresponding changes in metabo-
lism that match the dynamic nature of immune cells.
Quiescent lymphocytes have limited biosynthetic demands 
and metabolic pathways are tuned toward efficiently metaboliz-
ing glucose through glycolysis coupled to oxidative phosphoryla-
tion (oxphos) to make energy, i.e., adenosine triphosphate (ATP) 
(Figure  1). Upon immune activation, lymphocytes, including 
NK cells, increase glucose metabolism through glycolysis metab-
olizing much of the glucose into lactate, which is secreted from 
the cell, a process called “aerobic glycolysis” (14–17). Aerobic 
glycolysis is adopted by cells engaging in robust growth and 
proliferation because it provides the biosynthetic precursors that 
are essential for the synthesis of nucleotides, amino acids, and 
lipids (Figure 1) (18, 19). Therefore, for cells engaged in aerobic 
glycolysis, the primary function of glucose has shifted from a 
fuel to generate energy to a source of carbon that can be used for 
biosynthetic purposes (18).
Beyond the biochemistry of energy production and cellular 
biosynthesis, it has emerged that metabolism also plays a direct 
role in controlling immune signaling and immune cell effector 
functions (20). For instance, the glycolytic enzyme GAPDH also 
controls the expression of immunological molecules in both 
myeloid cells and lymphocytes through binding to the 3′UTR 
of mRNA (21, 22). In addition, certain metabolic intermedi-
ates have emerged as important signaling molecules, e.g., the 
glycolytic intermediate phosphoenolpyruvate regulates Ca2+ 
signaling and nuclear factor of activated T cells activity during 
T cell activation (23).
nK CeLL MeTABOLiSM
Murine nK Cells
In mice, NK cells develop and mature in the bone marrow and 
expression levels of CD11b and CD27 can be used to define 
subset progression to terminally differentiated naïve NK cells. 
Immature cells had higher expression of nutrient receptors CD71 
(transferrin receptor) and CD98 (l-amino acid transporter), 
and higher uptake of 2-NBDG (a fluorescent glucose analog) 
presumably to facilitate the metabolic demands of proliferation 
and differentiation (16). All these measurements reduced as cells 
matured such that resting naïve NK cells had a phenotype that 
was more characteristic of a quiescent lymphocyte. This was also 
reflected in transcriptional profiles of metabolic genes analyzed 
with naïve cells enriched for genes associated with oxphos, fatty 
acid oxidation (FAO), and autophagy compared with proliferat-
ing progenitor cells (16). Keppel et al. had similar findings in 
that freshly isolated splenic NK cells had low levels of metabolic 
activity with a preference for oxphos rather than glycolysis (24). 
Short-term activation (4–6  h) with either cytokines or recep-
tor ligation did not significantly alter the metabolic pathways 
used by NK cells (24). However, when NK cells are stimulated 
with cytokine over longer periods of time, as might be expected 
in  vivo in response to infection, changes in NK  cell metabo-
lism become apparent. Activation of murine splenic NK  cells 
for 3–5  days with high concentrations of IL15 (100  ng/ml) 
upregulated both glycolysis and oxphos (16, 24). Our data with 
NK cells expanded from splenocytes and primed with low dose 
IL15 demonstrated significant upregulation of both glycolysis 
and oxphos in response to IL2 + IL12 for 18 h. Although both 
pathways were upregulated, there was a preferential increase 
in glycolysis, a finding that parallels metabolic changes in CD8 
effector T  cells. Whether other fuels such as fatty acids and 
glutamine are important for NK cell metabolism and function 
is, to date, largely unexplored.
The mammalian target of rapamycin complex 1 (mTORC1) is 
considered a master regulator of immunology and metabolism. 
Increasingly, the delineation between these activities blurs as the 
importance of metabolism on immune cell function is appreci-
ated. mTORC1 was shown to be important for the development 
and maturation of murine NK cells and is strongly upregulated 
in mature NK cells in response to IL2 or IL15 (14, 16), cytokines 
that potently activate NK  cell functions. mTORC1 activity 
is required for the increased glycolysis observed in NK  cells 
stimulated for 18 h with IL2/IL12 or high dose IL15 (14, 17). 
The exact mechanisms by which mTORC1 controls NK  cell 
metabolism have not yet been described, though based on stud-
ies in T  lymphocytes the transcription factors HIF1α or cMyc 
are likely to be involved (20). mTORC2 signaling through the 
kinases Akt and SGK1 has recognised roles in regulating the 
differentiation of T cell subsets (25–27). Interestingly, while Akt 
regulates cellular metabolism in various cell types, this is not 
the case in IL2-maintained CD8 cytotoxic T cells (26). A role 
for mTORC2 in NK  cell metabolism and function remains to 
be investigated.
It is clear that NK  cells alter their metabolism in tandem 
with acquisition of enhanced effector functions but this does 
not necessarily imply a direct relationship between the two. A 
range of experimental approaches have been used to interfere 
with particular metabolic pathways to test the impact on NK cell 
function. These approaches demonstrated that direct metabolic 
restriction of glycolysis results in decreased NK cell effector func-
tion (14, 24).
Natural killer cells are part of a wider family of innate lymphoid 
cells (ILCs) and to date nothing is known about how cellular 
metabolism impacts upon the other ILC subsets. However, one 
study has highlighted a role for mTORC1 for cytokine production 
in type 2 ILCs, which might suggest that metabolic changes are 
involved (28).
FiGURe 1 | The differing metabolic phenotypes of quiescent versus activated lymphocytes. (A) Adenosine triphosphate (ATP) is the key molecule that 
provides energy for cellular processes. Maintaining cellular ATP levels is essential for bioenergetic homeostasis and cell survival. Glucose, a key fuel source for 
mammalian cells, can be metabolized via two integrated metabolic pathways, glycolysis and oxidative phosphorylation (oxphos), that efficiently generate ATP. 
Glycolysis converts glucose to pyruvate that, following transportation into the mitochondria, is further metabolized to CO2 by the Krebs cycle fueling oxphos and ATP 
synthesis. In addition to the breakdown of glucose via glycolysis, cells have the ability to metabolize alternative substrates including fatty acids by β-oxidation and 
glutamine by glutaminolysis, which feed into the Krebs cycle and drive oxphos. (B) Aerobic glycolysis supports biosynthetic processes of the cell as it allows the 
uptake of larger amounts of glucose and the maintenance of elevated glycolytic flux. Glycolytic intermediates are then diverted into various pathways for the 
synthesis of biomolecules that support biosynthetic processes. For instance, glucose-6-phosphate (G6P) generated by the first step in glycolysis can feed into the 
pentose phosphate pathway (PPP) to support nucleotide synthesis. This pathway also generates NADPH, a cofactor that is essential for various biosynthetic 
processes including lipid synthesis. Glucose can also be converted into cytoplasmic acetyl-CoA via citrate in the Krebs cycle for the production of cholesterol and 
fatty acids for lipid synthesis. Other glycolytic intermediates can also be converted into biomolecules used for protein and lipid synthesis. During aerobic glycolysis a 
significant proportion of pyruvate is also converted to lactate and secreted from the cell. Lactate export is important as it allows glycolysis to be sustained at an 
elevated rate. Alternative fuels including glutamine feed into the Krebs cycle and can also supply biomolecules for biosynthetic processes under certain conditions. 
DHAP, dihydroxyacetone phosphate, GP, glycerate 3-phosphate, Ser, serine; Ala, alanine.
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Human nK Cells
While less is known about human NK cell metabolism, it is likely 
that distinct phenotypic and functional NK cell subsets will have 
characteristic metabolic signatures. CD56 expression levels have 
long been used to define peripheral blood NK  cells subsets in 
humans. CD56dim NK  cells account for approximately 90% of 
circulating NK cells (2). These cells express CD16 and KIR and 
are more cytotoxic. By contrast, CD56bright cells predominate in 
tissues. They are less good at killing (granzyme B expression must 
be induced by cytokine) but are more potent at IFNγ production. 
Although there is strong evidence demonstrating that CD56bright 
cells can differentiate into CD56dim cells, both populations are 
maintained at a steady state in the peripheral blood of normal 
healthy individuals, suggesting that CD56brights are not merely a 
precursor in a developmental pathway and that they may have 
particular specialized functions, possibly related to tissue traf-
ficking and immunosurveillance. We have recently described that 
CD56bright and CD56dim subsets can also be distinguished in terms 
of their metabolism (15).
mTORC1 is a key regulator of metabolic responses and 
multiple cytokines have been shown to induce mTORC1 activ-
ity in human NK  cells (15, 16, 29). Interestingly, mTORC1 
was much more strongly activated in CD56bright cells and these 
cells responded more strongly to cytokine in terms of nutrient 
receptor expression and 2-NBDG uptake. This ensures that 
CD56bright cells that produce large amounts of IFNγ can meet 
the associated increased biosynthetic and metabolic demands 
of their specialized functional activity. However, the exact role 
for mTORC1 in CD56bright and CD56dim NK cells requires further 
investigation as initial observations show mTORC1 is required 
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for IL2-induced, but not IL12/IL15-induced, metabolic responses 
(15). Interestingly, in line with the observations that CD56bright 
NK cells are more metabolically responsive to cytokine stimula-
tion, metabolic restriction had a greater impact upon the function 
of CD56bright versus CD56dim NK cells (15).
More recently, within the CD56dim subset, progress has been 
made in delineating adaptive (cells that have experienced HCMV) 
and canonical NK cells. Cell surface, intracellular markers, and 
epigenetic signatures have been defined and important functional 
differences have been defined (30, 31). It is likely that these sub-
sets will be characterized by different metabolic pathway usage 
and based on similarities between adaptive NK cells and memory 
T cells, it seems reasonable to predict that adaptive NK cells may 
be characterized by preferential use of FAO metabolism to fuel 
oxphos (32). In mice, using Ly49H to identify cytomegalovirus 
(CMV)-experienced NK cells will also be informative in terms 
of metabolic analyses and data are already starting to emerge to 
support that NK cell metabolic responses will play a role in the 
formation of NK cell memory (see below). Finally, it will be inter-
esting to investigate if there are differences between licensed and 
unlicensed NK cells in terms of their metabolism (33). If normal 
responsive NK cells, i.e., licensed, use mTORC1 to metabolically 
reprogramme and upregulate functions, we might predict that 
unlicensed NK  cells which are functionally hyporesponsive 
may be deficient in terms of mTORC1 activation in response 
to cytokine, which would have a downstream impact on their 
metabolism and function.
nK CeLL MeTABOLiSM AnD viRAL 
inFeCTiOnS
Most of what is known about metabolic changes in lymphocytes 
during viral infections come from studies on CD8 T  cells and 
thusfar, very little is known about metabolic changes that occur 
in NK cells during viral infection. The underlying principles of 
CD8 T  cells metabolism during viral infection are likely to be 
similar in NK cells, though there may be differences in particular 
NK cell subsets (33). The CD8 T cell response to virus consists 
of an initial expansion of virus-specific T  cells that carry out 
effector functions against virally infected cells. During this 
process, metabolism is altered from utilization of oxphos (fueled 
by glucose and glutamine) and FAO in naïve T cells (34, 35) to 
increased glycolysis and oxphos in effector T cells (36–39). As 
expected, mitochondrial mass, ATP levels, and spare respiratory 
capacity (SRC) can all be increased in effector cells (39). mTORC1 
is a key in terms of driving metabolic reprogramming of T cells 
(40, 41) and although much remains to be elucidated in terms 
of molecular mechanisms, PGC1α, a regulator of mitochondrial 
biogenesis has recently been implicated in a number of murine 
models (38, 39). After immune control has been established by 
elimination of the pathogen, the expanded effector population 
contracts to generate a small pool of long-lived memory cells 
that have the capacity to react quickly and more effectively upon 
subsequent exposure to the same virus. These memory cells 
preferentially use FAO to fuel oxphos to provide energy (32, 42). 
They also have increased mitochondrial mass and mitochondrial 
SRC (compared to naïve or effector T  cells) which gives them 
a bioenergetics advantage for their increased effector functions 
upon activation.
However, sometimes the immune system fails to control 
the pathogen and chronic viral infections can ensue that are 
associated with increased long-term morbidity and mortality 
in patients, e.g., HIV-1 and hepatitis B or C infections. From 
an immunology perspective, lymphocytes in these patients 
develop an “exhausted” phenotype and although present, they 
are hyporesponsive. Metabolically, exhausted cells have impaired 
mitochondrial responses that paradoxically include increased 
mitochondrial mass but reduced oxphos, SRC, and mitochon-
drial membrane potential (38, 43). For at least LCMV infections, 
mitochondrial ROS is increased in parallel (38). There is a general 
consensus that defective mitochondrial function is a characteristic 
of chronic infection and that the reduced mitochondrial activity 
may force the cells to ineffectively utilize glycolysis under condi-
tions where glucose availability is limited. Thus, while we do not 
fully understand the why and how, it is clear that different T cell 
subsets are characterized by using different metabolic pathways 
for their survival and function.
Although little is yet known about how metabolism in NK cells 
impacts upon viral infections, information is starting to emerge, 
albeit indirectly. There is a large body of literature supporting the 
importance of NK cells in the immune response to CMV with 
the demonstration that CMV can shape the NK cell repertoire 
and generate NK  cells that have memory for CMV (6). While 
the in-depth metabolic changes in NK cells during CMV infec-
tion remain to be characterized, a sneak-preview is provided by 
O’Sullivan et  al. that show reduced mitochondrial polarization 
and increased mtROS in effector NK cells (44). As these effector 
cells died back to generate a pool of memory cells in a mitophagy-
dependent manner, mitochondrial potential in memory NK cells 
was restored, concomitant with reduced mtROS, suggesting a role 
for metabolic regulation of innate immune memory as has been 
seen for memory CD8 cells (45).
Furthermore, Marcais et al. have demonstrated that intrinsic 
mTORC1 plays an important role in the NK  cell response to 
MCMV infection, including proliferation, expression of gran-
zyme B, and IFNγ production (to some but not all stimuli) (16); 
however, the relative contribution of mTORC1 to metabolism 
versus direct effects on functions remains to be elucidated.
iMPLiCATiOnS FOR DiSeASe
Metabolism remains an unexplored landscape that holds great 
potential for therapeutic manipulation of NK cells in a variety of 
diseases including cancer and chronic viral infection. There are 
several potential ways in which metabolism of NK cells could be 
targeted to improve outcome for cancer patients.
It has been known for a long time that NK cell functions are 
impaired in many different forms of cancer (46–48). Indeed, 
various mouse models have shown that NK  cells become 
exhausted during cancer (49, 50). In addition to no longer being 
effective against cancer, reduced NK activity also leaves patients 
susceptible to infections. Therefore, activation of NK cells in vivo 
is an attractive therapeutic strategy. We predict that NK  cell 
metabolism in these patients will be severely compromised and 
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restoring normal metabolism might be key to restoring function. 
Check-point blockade inhibitors including anti-PD1 and -PDL1 
have revolutionized many cancer treatments. They function in 
part by restoring immune activity in exhausted T  cells and a 
recent report suggests that restoring metabolism in T cells can 
contribute to this (38). There is some evidence that NK cells from 
multiple myeloma patients expressed PD1 and that blocking PD1 
enhanced NK  cell functions against tumor cells (51). Indeed, 
anti-PD1 blockade increased expression of genes associated 
with NK cell cytotoxicity during in vivo therapy for cancer (52). 
There is also evidence that anti-Tim3 restored NK cell function in 
NK cells from patients with metastatic melanoma (53). However, 
the impact of check-point inhibitors on NK cell functions dur-
ing cancer treatment has not yet been extensively investigated. 
Understanding how NK  cell metabolism is altered in cancer 
will provide valuable information regarding how best to restore 
metabolism and function in exhausted NK cells.
As mentioned earlier, NK cells are used therapeutically in a 
variety of settings including adoptive transfer therapy and anti-
body-mediated immunotherapy for cancer. Adoptive transfer of 
allogeneic haploidentical NK cells is currently used as a treatment 
for AML (54–56). One benefit of allogeneic NK cells is the ability 
to culture the cells ex vivo, e.g., in the presence of cytokine, to 
increase immune function. Understanding how metabolism con-
tributes to NK cell function will provide the opportunity to stra-
tegically manipulate metabolism of NK cells, which will translate 
into more effective anticancer activity in vivo. Proof of principle 
for this comes from preclinical studies in which altering T cell 
metabolism improved cancer outcome in an adoptive cellular 
immunotherapy setting. In a seminal paper, it was demonstrated 
that mitochondrial architecture not only alters metabolism but 
also function (57). Exploiting this, IL2-treated T effector cells 
were pharmacologically manipulated with drugs that promoted 
mitochondrial fusion and increased oxphos efficiency ex vivo. As a 
result, these T cells that were adoptively transferred had increased 
longevity in vivo and improved overall survival in this lymphoma 
model (57). Ex vivo manipulation of cells for adoptive transfer has 
the advantage of being able to use drugs and cytokines that may 
be toxic for direct in vivo administration. As NK cells are already 
used clinically for adoptive transfer therapy, understanding and 
improving metabolism of NK  cells for improved function and 
improved clinical responses is a realistic goal.
Natural killer cells are also important in antibody immu-
notherapy for a variety of cancers including breast cancer 
FiGURe 2 | Proposed bimodal model of natural killer (nK) cell activation. NK cells are best characterized for their rapid, early immune responses after 
exposure to pathogen. Among the important innate cytokines that activate NK cells are IL12, IL15, and IL18. NK cells carry out direct cytotoxicity of target cells and 
are potent producers of IFNγ. There are relatively modest changes in NK cell metabolism at these early time points suggesting that this first wave of NK activity relies 
on cells that are primed and ready to go without the need for substantial metabolic reprogramming. However, we know that NK cells can function at extended time 
periods beyond the first few days post-infection. IL2, produced by activated T cells, is one cytokine that is important in this process. IL2 drives mTORC1-dependent 
glycolytic reprogramming of NK cells which we believe is critical for the sustained effector functions of this second generation of NK cells, allowing them to work in 
parallel with the adaptive immune response.
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(anti-Her2), lymphoma (anti-CD20), and neuroblastoma (anti-
GD2), reviewed in Ref. (13). Increasing ADCC of NK cells will be 
beneficial for these patients. Metabolism provides an opportunity 
to do this as, similar to what has been observed for T cells, it is 
likely that particular functional subsets, e.g., adaptive NK  cells 
that have high ADCC (30, 31), will have a different metabolism 
compared to canonical NK  cells. By understanding NK  cell 
metabolism in these subsets, we have the potential to manipulate 
metabolism to increase ADCC.
It is important to note that many therapies that identify new 
treatments for cancer do so in isolation from the immune system 
and do not consider the potential negative impacts of particular 
treatments on the immune system, e.g., rapamycin, which 
inhibits mTORC1, has recently been proposed as a treatment for 
neuroblastoma (58). However, rapamycin is also likely to inhibit 
metabolic reprogramming in NK  cells (for which mTORC1 is 
required) and may potentially impair functions that would be 
beneficial to the patient.
COnCLUDinG PeRSPeCTiveS
Overall, the data lead us to propose a bimodal model of NK cell 
immune function in terms of metabolic responses (Figure 2). 
Circulating NK cells respond rapidly upon activation by early 
innate cytokines and are important in the innate immune 
response. There are only modest changes in cellular metabo-
lism associated with these activities and thus, metabolism is 
unlikely to impact significantly in regulating these functions. 
However, we know that NK  cells have relatively low levels of 
CD25 and this becomes upregulated on NK cells during early 
activation to give a high-affinity IL2 receptor (59). This now 
enables the NK  cell to respond to IL2 which is produced as 
part of the adaptive immune response. Thus, a second wave of 
NK  cell activation commences to produce sustained NK  cell 
activation and functioning in parallel and in concert with the 
adaptive immune response. These exact activities remain to be 
defined but could include both effector and regulatory func-
tions (60, 61). We suggest that metabolic reprogramming, in 
particular increased levels of glycolysis, is an essential part of 
this second wave and that mTORC1 is a critical component 
of the process. In this model, it is likely that effector func-
tions and metabolic changes are more sensitive to the effects 
of rapamycin and that metabolism may have a more profound 
effect on these later stage effector functions. In support of this, 
direct glycolytic restriction appears to have a greater effect on 
cytokine-stimulated NK cells that have been activated for longer 
periods and undergone glycolytic reprogramming compared to 
short-term stimulated NK cells (14, 15, 24). Understanding how 
NK  cell metabolism is regulated at these longer time periods 
will be important for our understanding of NK  cell dysfunc-
tion in chronic diseases. Ultimately, this knowledge will help to 
refine existing therapies but also provide new opportunities for 
NK cell-based immunotherapies for the treatment of cancer and 
chronic viral infections.
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